Oculis Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCS research report →
Range $26 – $50
Price Chart
About the company
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease.
- CEO
- Riad Sherif
- IPO
- 2021
- Employees
- 60
- HQ
- Zug, ZG, CH
Get TickerSpark's AI analysis on OCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $751.21M
- P/E
- -7.51
- Fwd P/E
- 17.72
- PEG
- -0.13
- P/S
- 2473.05
- P/B
- 2.94
- EV/EBITDA
- -7.69
- Div Yield
- 0.00%
- Gross Margin
- 35.21%
- Op Margin
- -35874.24%
- Net Margin
- -32780.20%
- ROE
- -42.92%
- ROIC
- -38.94%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-79,145,361
- Net Income
- $-94,508,181-10.2%
- EPS
- $-1.81+14.6%
- OCF Growth
- -31.0%
- FCF Growth
- -31.0%
- 52W High
- $34.48
- 52W Low
- $10.52
- 50D MA
- $12.27
- 200D MA
- $21.45
- Beta
- 0.23
- RSI (14)
- 55
- Avg Volume
- 661.79K
No earnings-call transcripts are available for OCS yet.
- Free Float
- 64.8%
- Shares Outstanding
- 57.17M
- Float Shares
- 37.03M
of shares held by institutions
41 13F filers
Held by 6 ETFs
Biggest fund positions in OCS by dollar value.
Our OCS coverage
Recent articles, reports, and earnings notes.
No research on OCS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCS report →Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
globenewswire.com · Aug 14
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?
zacks.com · Aug 14
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company
globenewswire.com · Aug 10
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 6
Oculis Reports Q2 2026 Financial Results and Provides Company Update
globenewswire.com · Aug 6
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
globenewswire.com · Aug 3
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
globenewswire.com · Aug 3
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
globenewswire.com · Aug 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.